Results 201 to 210 of about 836,777 (260)

New Treatment Options for Pancreatic Neuroendocrine Tumors: A Narrative Review. [PDF]

Cancers (Basel)
Romanowicz A, Fudalej M, Asendrych-Woźniak A, Badowska-Kozakiewicz A, Nurzyński P, Deptała A.   +5 more
europepmc   +1 more source

Size alone is not enough: Ki-67 and invasion patterns identify high-risk pancreatic neuroendocrine tumors. [PDF]

Arq Bras Cir Dig
Cortelli DASM, Torres SM, Farias IC, Diniz AL, Ribeiro HSC, Godoy AL, Gonçalves CA, Coimbra FJF.   +7 more
europepmc   +1 more source

Hypoattenuation Pattern on Contrast-Enhanced Computed Tomography Predicts Poor Prognosis in Patients with Pancreatic Neuroendocrine Tumors. [PDF]

J Clin Med
Kojima I, Hashimoto S, Yamazato Y, Shibata R, Kamikihara Y, Toyodome K, Hamada T, Hinokuchi M, Arima S, Tanoue S, Sasaki F, Ejima F, Takumi K, Yoshiura T, Kanmura S.   +14 more
europepmc   +1 more source

Real-World-Feasible Immunohistochemistry of ATRX, DAXX, and Menin Identifies a Subgroup of Non-Functioning Pancreatic Neuroendocrine Tumors with low Recurrence Risk to Guide De-Escalating Surveillance. [PDF]

Endocr Pathol
Verschuur AVD, Hackeng WM, Jairam J, Eldem B, Westendorp JS, Vriens MR, Valk GD, Pea A, Salvia R, Lawlor RT, Scarpa A, Luchini C, Heaphy CM, Hong SM, Marinoni I, Perren A, Dreijerink KMA, van Dijkum EJMN, Sarasqueta AF, Singhi AD, Elias SG, Brosens LAA.   +21 more
europepmc   +1 more source

Medical Management of Well-Differentiated Pancreatic Neuroendocrine Tumors: From Conventional Therapies to Emerging Strategies. [PDF]

J Clin Med
Sung MJ, Park N.
europepmc   +1 more source

CDKN2A homozygous deletions and TSC2 somatic mutations in metastatic pancreatic neuroendocrine tumors. [PDF]

NPJ Precis Oncol
Jesus TT, Ferrando L, Rodrigues L, Martins RS, Cardoso L, Lopes JM, Soares P, Da Cruz Paula A, Vinagre J.   +8 more
europepmc   +1 more source

Artificial Intelligence-Assisted Endoscopic Ultrasound-Guided Ablation of Pancreatic Neuroendocrine Tumors: Toward Precision Diagnosis, Risk Stratification, and Personalized Therapy. [PDF]

Cureus
Salman A, Elewa A, Safina A, Marwan A.
europepmc   +1 more source

DNA methyltransferase 1 correlates with immune modulation in pancreatic neuroendocrine tumors. [PDF]

Sci Rep
Saleh Z, Nation RJ, Moccia MC, Kalola A, Ghanem Y, Joshi H, Joneja U, Li Y, Spitz F, Gao T, Hong YK.   +10 more
europepmc   +1 more source

Short-term surgical outcomes for patients with non-functional pancreatic neuroendocrine tumors are unaffected by chronological age. [PDF]

Surg Open Sci
Aghamaliyev U, Zamparas A, Seidel G, Meyer Y, Jafarova G, Koch D, Hofmann FO, Koliogiannis D, Ilmer M, Karimbayli J, Werner J, Renz BW.   +11 more
europepmc   +1 more source

Tumor-derived apolipoprotein E confers resistance to temozolomide in pancreatic neuroendocrine tumors. [PDF]

Cell Death Dis
Lou X, Shi Y, Qin Y, Zhang W, Ye Z, Wang F, Wang Y, Ding T, Jing D, Fan G, Zhang Y, Chen X, Xu X, Yu X, Ji S, Xu J.   +15 more
europepmc   +1 more source